12:00 AM
Nov 10, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lucitanib: Phase II started

Clovis began an open-label, international Phase II trial to evaluate once-daily oral lucitanib, starting at 15 mg/day, in 28-day cycles in about 40 patients. The dose can be reduced in 2.5 mg/day increments to 5 mg/day. Clovis has ex-Chinese rights to lucitanib...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >